Promising Improvements in Mild Cognitive Impairment With Investigational NA-831

Promising Improvements in Mild Cognitive Impairment With Investigational NA-831

Researchers from NeuroActiva, Inc. presented results of their randomized, double-blind, placebo-controlled phase 2A clinical trial of NA-831.

Tramiprosate Associated With High Response, Favorable Safety in APOE ε4 Homozygotes With Mild Alzheimer's

Tramiprosate Associated With High Response, Favorable Safety in APOE ε4 Homozygotes With Mild Alzheimer's

Researchers assessed individual patient responses as well as overall response rates to oral tramiprosate and the effect of response on clinical outcomes.

Twice-Daily Oxaloacetate Activates Brain Bioenergetic Metabolism in Alzheimer Disease

Twice-Daily Oxaloacetate Activates Brain Bioenergetic Metabolism in Alzheimer Disease

The study assessed the pharmacokinetics and pharmacodynamics of 2 doses of oxaloacetate in patients with Alzheimer disease.

New Monoclonal Antibody BAN2401 Reduces Amyloid Plaques, Improves Cognition in Alzheimer's

New Monoclonal Antibody BAN2401 Reduces Amyloid Plaques, Improves Cognition in Alzheimer's

Initial data from Study 201, as announced in December 2017, showed BAN2401 did not meet the primary endpoint.

Investigating the Effects of Z-Drugs in Dementia Patients With Sleep Disturbances

Investigating the Effects of Z-Drugs in Dementia Patients With Sleep Disturbances

Existing data from the the UK Clinical Practice Research Datalink (CPRD) and 3 clinical studies of PwD were used to evaluate the association between Z-drug administration and the incidence of adverse events.

Metformin Associated With Increased Dementia Risk in African Americans With Diabetes

Metformin Associated With Increased Dementia Risk in African Americans With Diabetes

Participants in this study were part of the Indianapolis-Ibadan Dementia Project that took place from 1992 to 2011 and were assessed for dementia every second or third year during follow-up.

Pimavanserin Confers Greater Improvements in Alzheimer Disease Psychosis vs Placebo

Pimavanserin Confers Greater Improvements in Alzheimer Disease Psychosis vs Placebo

Pimavanserin is currently approved in the United States for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Transdermal Buprenorphine Not Well Tolerated in Dementia

Transdermal Buprenorphine Not Well Tolerated in Dementia

The researchers conducted a 13-week study that included 162 individuals with advanced dementia and considerable depression residing in nursing homes in Norway.

Cannabinoid Shows Promise for Reducing Agitation, Aggression in Alzheimer Disease

Cannabinoid Shows Promise for Reducing Agitation, Aggression in Alzheimer Disease

Although treatment with nabilone significantly improved agitation, cognition, and nutrition, the authors cautioned that sedation should be closely monitored.

Sugary Drinks, Other Added Sugars May Up Risk for Alzheimer Disease

Sugary Drinks, Other Added Sugars May Up Risk for Alzheimer Disease

Drinking sugary beverages has been previously linked to markers of preclinical Alzheimer disease, but the risk associated with consuming added sugars is not established.